BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38733420)

  • 1. The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review.
    Matsubayashi H; Todaka A; Tsushima T; Kiyozumi Y; Harada R; Ishihara E; Higashigawa S; Ohike N; Sakamoto H; Sato J; Ishiwatari H; Sugiura T; Uesaka K
    Fam Cancer; 2024 May; ():. PubMed ID: 38733420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant.
    Sunami T; Yamada A; Kondo T; Kanai M; Nagai K; Uchida Y; Yokode M; Matsumori T; Uza N; Murakami H; Yamada T; Muto M
    Pancreas; 2022 Oct; 51(9):1258-1262. PubMed ID: 37078954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    Li M; Mou Y; Hou S; Cao D; Li A
    Medicine (Baltimore); 2018 Nov; 97(45):e13113. PubMed ID: 30407325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
    Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
    World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
    Wu C; Fan M; Hu Y
    Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma.
    Urabe M; Ikezawa K; Kozumi K; Kai Y; Takada R; Mukai K; Nakabori T; Uehara H; Akita H; Ohkawa K
    Clin J Gastroenterol; 2024 May; ():. PubMed ID: 38743170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
    Mandelker D; Marra A; Zheng-Lin B; Selenica P; Blanco-Heredia J; Zhu Y; Gazzo A; Wong D; Yelskaya Z; Rai V; Somar J; Ostafi S; Mehta N; Yang C; Li Y; Brown DN; da Silva EM; Pei X; Linkov I; Terraf P; Misyura M; Ceyhan-Birsoy O; Ladanyi M; Berger M; Pareja F; Stadler Z; Offit K; Riaz N; Park W; Chou J; Capanu M; Koehler M; Rosen E; O'Reilly EM; Reis-Filho JS
    J Clin Oncol; 2023 Nov; 41(33):5151-5162. PubMed ID: 37607324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.
    Ohara Y; Oda T; Enomoto T; Hisakura K; Akashi Y; Ogawa K; Owada Y; Domoto Y; Miyazaki Y; Shimomura O; Kurata M; Ohkohchi N
    World J Surg Oncol; 2018 Aug; 16(1):158. PubMed ID: 30075727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.
    Prete AA; Procaccio L; Bergamo F; Rasola C; Nappo F; Zagonel V; Lonardi S
    Curr Oncol; 2022 Jan; 29(2):544-550. PubMed ID: 35200549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic Acinar Cell Carcinoma with Germline BRCA2 Mutation and Severe Pancreatic Panniculitis: A Case Report.
    Dreikhausen L; Schulte N; Belle S; Weidner P; Moersdorf J; Reissfelder C; Ebert MP; Zhan T
    Visc Med; 2021 Oct; 37(5):447-450. PubMed ID: 34722729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.
    Lelong M; Raoul JL; Touchefeu Y; Berthelot JM; Arnolfo P; Matysiak-Budnik T; Senellart H
    Clin Case Rep; 2022 Dec; 10(12):e6718. PubMed ID: 36523391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic
    Schwartzberg LS; Kiedrowski LA
    Ther Adv Med Oncol; 2021; 13():17588359211006962. PubMed ID: 33868464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection.
    Watanabe T; Nagaoka Y; Kimura N; Fukasawa M; Shirai Y; Hirano K; Shibuya K; Yoshioka I; Hamashima T; Fujii T
    Clin J Gastroenterol; 2024 Jun; ():. PubMed ID: 38836973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
    Al-Hader A; Al-Rohil RN; Han H; Von Hoff D
    World J Gastroenterol; 2017 Dec; 23(45):7945-7951. PubMed ID: 29259370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?
    Garajová I; Balsano R; Gelsomino F; Leonardi F
    Tumori; 2022 Dec; 108(6):NP30-NP33. PubMed ID: 36299234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.
    Hall JC; Marlow LA; Mathias AC; Dawson LK; Durham WF; Meshaw KA; Mullin RJ; Synnott AJ; Small DL; Krishna M; von Hoff D; Schüler J; Hart SN; Couch FJ; Colon-Otero G; Copland JA
    J Transl Med; 2016 May; 14(1):129. PubMed ID: 27165126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.